Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
09.06.Metsera posts weight loss data for amylin analog, teeing up monthly GLP-1 combo plans
06.06.TegMine, with ex-Stemcentrx scientists at the helm, bags tech from OBI to help fuel ADC ambitions
06.06.Otsuka's kidney disease drug halves UPCR levels in phase 3 study
05.06.'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape
05.06.Seyltx reserves option to boost chronic cough pipeline with 8 GluN2B antagonists
05.06.Chasing Sarepta, RegenXBio links DMD gene therapy to improved outcomes
05.06.Corcept unveils promising survival data from failed phase 2 ALS trial
05.06.Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T cell engager
04.06.Rapt Therapeutics cuts staff for 2nd time in less than a year, continuing fallout from FDA hold
04.06.With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field
04.06.Vigil's rare brain disease drug flunks phase 2 study, but Sanofi takeover is unaffected
04.06.Bayer's Vividion secures rights to world's only clinical-stage WRN inhibitor from partner Roche
04.06.Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators
03.06.Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M
03.06.Plexium cuts staff, realigns resources to support protein degrader pipeline
03.06.BioAge inks option agreement for Chinese biotech's obesity asset on heels of earlier APJ agonist setback
03.06.FDA, facing 4% budget cut, launches generative AI tool Elsa a month ahead of schedule
03.06.Transpire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease
03.06.Merck made $3B-plus offer for MoonLake-and could revive interest in late-phase biotech: FT
03.06.ASCO: OSE shares 65% overall survival rate behind therapeutic cancer vaccine's phase 2 win
02.06.'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race
02.06.Precision medicine's next frontier: unlocking the power of biospecimens
02.06.ASCO's bubble of hope: Execs focus on 'rewriting textbooks' in cancer care at conference
02.06.Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab
02.06.Bristol Myers inks $11B BioNTech deal to join bispecific gold rush, leaping ahead of Merck and Pfizer